Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma

Phase 1

Completed

• Conditions: Superficial Basal Cell Carcinoma
• Interventions: Drug: API 31510 3% Topical Cream; Drug: API 31510 1.5% Topical Cream; Other: Placebo

• Registration Number: NCT00604890
• Lead Sponsor: BPGbio

Brief Summary

The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the treatment of superficial basal cell carcinomas by API 31510 topical cream. The study population will include one hundred and sixty (160) otherwise healthy male or female adults with one or more histologically confirmed superficial basal cell carcinoma lesions. One target lesion with an area of less than one inch will be designated for study treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-01-17
• Study First Submitted QC: 2008-01-17
• Study First Posted: 2008-01-30
• Study Start: 2008-03
• Primary Completion: 2010-01
• Study Completion: 2010-01
• Results First Submitted: 2019-01-22
• Status Verified: 2019-02
• Results First Submitted QC: 2019-02-12
• Results First Posted: 2019-03-05
• Last Update Submitted: 2025-02-14
• Last Update Posted: 2025-02-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 186

Inclusion Criteria

• Male or female adults ≥ 18 years of age
• Primary, histologically confirmed sBCC with a minimum area of 0.5 cm2 and with a maximum diameter of 2.0 cm target sBCC lesion suitable for excision
• Histological diagnosis made no more than 4 weeks prior to the screening visit
• Histological biopsy removed 25% or less of the target lesion
• No other dermatological disease in the sBCC target site or surrounding area
• Willing to refrain from using non-approved lotions or creams on the target site and surrounding area during the treatment period. Willing to refrain from washing the treated area for at least 8 hours following the application of study medication
• Willing to refrain from exposure to direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study
• Laboratory values for the tests listed in the Study Schedule on page 2 within the reference ranges as defined by the central laboratory, or "out of range" test results that are clinically acceptable to the investigator.
• Ability to follow study instructions and likely to complete all study requirements
• Written informed consent obtained, including consent for tissue to be examined and stored by the central dermatopathologist
• Written consent to allow photographs of the target sBCC lesion to be used as part of the study data
• For females of childbearing potential, a negative pregnancy test at screening and using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy)

Exclusion Criteria

• Pregnant or lactating
• Presence of known or suspected systemic cancer
• Histological evidence of nBCC, SCC, or any other tumor in the biopsy specimen
• Histological evidence of severe squamous metaplasia, infiltrative, desomoplastic or micronodular growth patterns in the biopsy specimen
• History of recurrence of the target sBCC lesion
• Evidence of dermatological disease or confounding skin condition in the treatment area, e.g., SCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema, xeroderma pigmentosa
• Concurrent disease or treatment that suppresses the immune system
• Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk
• Known sensitivity to any of the ingredients in the study medication
• Use of a tanning parlor or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the course of the study
• Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit
• Use of systemic retinoids within the 6 months prior to the screening period
• Treatment with systemic immunomodulators or immunosuppressants within the 6 months prior to the screening period
• Use of topical immunomodulators within 2 cm of the target BCC lesion within the 4 weeks prior to the screening period
• Treatment with the following topical agents within the 4 weeks prior to the screening visit: levulanic acid, 5-fluorouracil, coricosteroids, retinoids, diclofenac, hyaluronic acid, imiquimod
• Undergone a facial resurfacing procedure, i.e., chemical peel, laser resurfacing, dermabrasion, within the 6 months prior to the screening visit, if the target sBCC lesion is on the face
• Treatment with liquid nitrogen, surgical excision or curettage within 2 cm of the target sBCC lesion during the 4 weeks prior to the screening visit
• Elective surgery within 4 weeks prior to the screening visit, during the study, or 4 weeks after the treatment period
• Evidence of current chronic alcohol or drug abuse
• Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of the screening visit
• In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions of the protocol and complete the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	API 31510 3% Topical Cream	Active cream, 3% AM \& PM
2	API 31510 3% Topical Cream	Placebo cream AM ; 3% active cream PM
2	Placebo	Placebo cream AM ; 3% active cream PM
3	API 31510 1.5% Topical Cream	Placebo cream AM; 1.5% active cream PM
3	Placebo	Placebo cream AM; 1.5% active cream PM
4	Placebo	Placebo AM and PM

Primary Outcome Measures

Name	Time	Method
Number of Participants With Complete Response	10 weeks	To determine the number of participants with a complete response, defined as a negative histological examination of the sBCC lesion at Week 10 (4 weeks post-treatment).

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Partial Response	10 weeks	To determine the number of participants with a partial response, defined as a clinically significant decrease (ie, at least 50%) in the area of the sBCC lesion, computed as the product of the two principal diameters at Week 10 (4 weeks post-treatment)

Trial Locations

Locations (11)

Colorado Medical Research Center; 🇺🇸 Denver, Colorado, United States

Dermatology Associates and Research; 🇺🇸 Coral Gables, Florida, United States

Dermatology Clinical Research Center of San Antonio; 🇺🇸 San Antonio, Texas, United States

Long Island Skin Cancer and Dermatologic Surgery, PC; 🇺🇸 Smithtown, New York, United States

Burke Pharmaceuticals; 🇺🇸 Hot Springs, Arkansas, United States

Oregon Dermatology and Research Center; 🇺🇸 Portland, Oregon, United States

Education & Research Foundation; 🇺🇸 Lynchburg, Virginia, United States

Skin Surgery Medical Group, Inc.; 🇺🇸 San Diego, California, United States

Scott D. Glazer, M.D., S.C.; 🇺🇸 Buffalo Grove, Illinois, United States

Gwinnett Clinical Research; 🇺🇸 Snellville, Georgia, United States

Christie Clinic; 🇺🇸 Champaign, Illinois, United States